TY - JOUR
T1 - Prospects for new lung cancer treatments that target EMT signaling
AU - Otsuki, Yuji
AU - Saya, Hideyuki
AU - Arima, Yoshimi
N1 - Funding Information:
Grant sponsor: JSPS KAKENHI; Grant number: JP16K10473; Grant sponsor: MEXT KAKENHI; Grant number: JP22130007.
Funding Information:
We thank our laboratory members. This work was supported by JSPS KAKENHI Grant Number JP16K10473 (Y.A.) and MEXT KAKENHI Grant Number JP22130007 (H.S.).
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/3
Y1 - 2018/3
N2 - Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.
AB - Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462–472, 2018.
KW - ZEB1
KW - drug resistance
KW - epithelial-mesenchymal transition
KW - lung disease
UR - http://www.scopus.com/inward/record.url?scp=85042131564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042131564&partnerID=8YFLogxK
U2 - 10.1002/dvdy.24596
DO - 10.1002/dvdy.24596
M3 - Review article
C2 - 28960588
AN - SCOPUS:85042131564
SN - 1058-8388
VL - 247
SP - 462
EP - 472
JO - American Journal of Anatomy
JF - American Journal of Anatomy
IS - 3
ER -